Du Bois, J S <br/><br/>
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Mar 1997 
 - 1052-62 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.1997.15.3.1052  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antigens, CD<br/>Carcinoma, Renal Cell--blood<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Immunoglobulin G--adverse effects<br/>Immunophenotyping<br/>Interleukin-2--adverse effects<br/>Kidney Neoplasms--blood<br/>Male<br/>Melanoma--blood<br/>Middle Aged<br/>Monocytes<br/>Receptors, Tumor Necrosis Factor<br/>Receptors, Tumor Necrosis Factor, Type II<br/>Recombinant Fusion Proteins--adverse effects<br/>Skin Neoplasms--blood